Global IHC Daignostics Market

IHC Daignostics Comprehensive Study by Type (Antibodies (Primary antibodies, Secondary antibodies), Reagents (Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents), Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ), Kits (IHC Kits for Human tissue, IHC Kits for Animal tissue)), Application (Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ), Research applications (Drug development and Testing, Other), Forensic applications), End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Other) Players and Region - Global Market Outlook to 2030

IHC Daignostics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About IHC Daignostics
Immunohistochemistry is the name given to IHC Diagnostics. It's a microscopy technique for recognizing antigens and macromolecules found in cells. The presence and localization of the target protein in various types of cells, biological cycles, or even subcellular localization within complex tissues are all visualized via immunohistochemistry. This approach can be used for diagnostic purposes as well as a successful treatment program. The very sensitive identification of several proteins in the same sample, as well as the accessibility of protein-protein interaction detection, are two recent developments in the IHC technology. This method can be used for drug testing as well as disease diagnosis. Increasing automation and machine learning in immunohistochemistry (IHC), as well as the introduction of technologically improved immunohistochemistry solutions, are likely to propel the market forward significantly over the forecast period. Advances in IHC methods have increased the demand for it in illness diagnosis to a significant degree.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR8.1%


The leading market participants' high level of consolidation. To address the market's growing demand for IHC assays in cancer diagnostics, the industry's leading competitors are launching new products, merging and acquiring companies, and expanding regionally. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global IHC Daignostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (United States), Bio-Techne Corporation (United States), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (United States), Agilent Technologies, Inc. (United States), Abcam plc (UK), Becton, Dickinson, and Company (United States), PerkinElmer, Inc. (United States), Takara Bio, Inc. (Japan), Thermo Fisher Scientific, Inc. (United States), Diagnostic Biosystems, Inc. (United States), BioVision Inc. (United States), Rockland Immunochemicals, Inc. (United States) and Genemed Biotechnologies, Inc. (United States). are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are PHC Holdings Corporation (Japan), Cell Signaling Technology, Inc. (United States), Bio SB, Inc. (United States), Miltenyi Biotec (Germany), CANDOR Bioscience GmbH (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Eagle Biosciences, Inc. (United States), Biocare Medical, LLC (United States), Elabscience, Inc. (China) and Biogenex Laboratories (United States).

Segmentation Overview
AMA Research has segmented the market of Global IHC Daignostics market by Type (Antibodies [Primary antibodies, Secondary antibodies], Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents], Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ] and Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue]), Application (Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ], Research applications [Drug development and Testing, Other] and Forensic applications) and Region.



On the basis of geography, the market of IHC Daignostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals & Diagnostic Laboratories will boost the IHC Daignostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
In the field of IHC, technological improvements have been made., Reimbursement for IHC testing is available. and The increased demand for IHC in medication development

Market Growth Drivers:
The aging population and the consequent increase in the prevalence of chronic and infectious diseases and The Growing Demand due to New product launches

Challenges:
The Concern Related to a scarcity of qualified professionals and Recalls and product failures

Restraints:
The high degree of consolidation

Opportunities:
Personalized medicine is becoming more popular., Companion diagnostics are becoming increasingly important. and Emerging markets provide prospects for growth.

Market Leaders and their expansionary development strategies
In August 2021, Roche's VENTANA MMR RxDx companion diagnostic test for solid tumors defective in the MMR pathway obtained FDA clearance based on immunohistochemistry. The test identifies people who are candidates for GSK's JEMPERLI anti-PD1 immunotherapy. and In August 2021, Agilent's PD-L1 IHC 22C3 pharmDx assay for identifying oesophageal cancer patients for treatment with KEYTRUDA acquired a CE-IVD mark in Europe.
In June 2021, PathAI, At the American society of clinical oncology virtual scientific program 2021, a U.S.-based provider of AI-powered technology for pathological applications demonstrated a machine learning-based quality control tool built for HER2 testing in breast cancer., In January 2021, The ONCORE Pro, a fully automated in vitro diagnostic benchtop system for in-situ hybridization (FISH) and immunohistochemistry (IHC) applications, was introduced by Biocare Medical LLC. and In January 2021, Abcam and Shuwen Biotech (Shuwen) entered into a strategic alliance for developing and commercializing companion diagnostics (CDx). Under the agreement, Abcam is providing recombinant rabbit monoclonal antibodies to Shuwen Biotech for further immunohistochemical verification.


Analyst View
The pandemic's emergence has prompted researchers to concentrate on approaches for developing a vaccine for the Covid-19. Immunohistochemistry can be used to detect antigen distribution and localization of the Corona virus-2, hence assisting in the creation of vaccines as needed. Furthermore, with the pressing need to develop vaccines with fewer adverse effects and greater efficacy, the immunohistochemistry approach is being employed to develop an optimum prophylactic formula. The employment of this approach in the present pandemic is a need, and as a result, the market will continue to rise in the next years.

Key Target Audience
IHC Diagnostics Providers, Government Regulatory Bodies, Private Research Organization, Government Research Organization and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Antibodies [Primary antibodies, Secondary antibodies]
  • Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents]
  • Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ]
  • Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue]
By Application
  • Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ]
  • Research applications [Drug development and Testing, Other]
  • Forensic applications
By End User
  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The aging population and the consequent increase in the prevalence of chronic and infectious diseases
      • 3.2.2. The Growing Demand due to New product launches
    • 3.3. Market Challenges
      • 3.3.1. The Concern Related to a scarcity of qualified professionals
      • 3.3.2. Recalls and product failures
    • 3.4. Market Trends
      • 3.4.1. In the field of IHC, technological improvements have been made.
      • 3.4.2. Reimbursement for IHC testing is available.
      • 3.4.3. The increased demand for IHC in medication development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global IHC Daignostics, by Type, Application, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global IHC Daignostics (Value)
      • 5.2.1. Global IHC Daignostics by: Type (Value)
        • 5.2.1.1. Antibodies [Primary antibodies, Secondary antibodies]
        • 5.2.1.2. Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents]
        • 5.2.1.3. Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ]
        • 5.2.1.4. Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue]
      • 5.2.2. Global IHC Daignostics by: Application (Value)
        • 5.2.2.1. Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ]
        • 5.2.2.2. Research applications [Drug development and Testing, Other]
        • 5.2.2.3. Forensic applications
      • 5.2.3. Global IHC Daignostics by: End User (Value)
        • 5.2.3.1. Hospitals & Diagnostic Laboratories
        • 5.2.3.2. Academic & Research Institutes
        • 5.2.3.3. Other
      • 5.2.4. Global IHC Daignostics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global IHC Daignostics (Price)
      • 5.3.1. Global IHC Daignostics by: Type (Price)
  • 6. IHC Daignostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bio-Techne Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffman-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Agilent Technologies, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abcam plc (UK)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Becton, Dickinson, and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PerkinElmer, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takara Bio, Inc. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Diagnostic Biosystems, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. BioVision Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Rockland Immunochemicals, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Genemed Biotechnologies, Inc. (United States).
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global IHC Daignostics Sale, by Type, Application, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global IHC Daignostics (Value)
      • 7.2.1. Global IHC Daignostics by: Type (Value)
        • 7.2.1.1. Antibodies [Primary antibodies, Secondary antibodies]
        • 7.2.1.2. Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents]
        • 7.2.1.3. Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ]
        • 7.2.1.4. Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue]
      • 7.2.2. Global IHC Daignostics by: Application (Value)
        • 7.2.2.1. Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ]
        • 7.2.2.2. Research applications [Drug development and Testing, Other]
        • 7.2.2.3. Forensic applications
      • 7.2.3. Global IHC Daignostics by: End User (Value)
        • 7.2.3.1. Hospitals & Diagnostic Laboratories
        • 7.2.3.2. Academic & Research Institutes
        • 7.2.3.3. Other
      • 7.2.4. Global IHC Daignostics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global IHC Daignostics (Price)
      • 7.3.1. Global IHC Daignostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. IHC Daignostics: by Type(USD Million)
  • Table 2. IHC Daignostics Antibodies [Primary antibodies, Secondary antibodies] , by Region USD Million (2018-2023)
  • Table 3. IHC Daignostics Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents] , by Region USD Million (2018-2023)
  • Table 4. IHC Daignostics Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ] , by Region USD Million (2018-2023)
  • Table 5. IHC Daignostics Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue] , by Region USD Million (2018-2023)
  • Table 6. IHC Daignostics: by Application(USD Million)
  • Table 7. IHC Daignostics Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ] , by Region USD Million (2018-2023)
  • Table 8. IHC Daignostics Research applications [Drug development and Testing, Other] , by Region USD Million (2018-2023)
  • Table 9. IHC Daignostics Forensic applications , by Region USD Million (2018-2023)
  • Table 10. IHC Daignostics: by End User(USD Million)
  • Table 11. IHC Daignostics Hospitals & Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 12. IHC Daignostics Academic & Research Institutes , by Region USD Million (2018-2023)
  • Table 13. IHC Daignostics Other , by Region USD Million (2018-2023)
  • Table 14. South America IHC Daignostics, by Country USD Million (2018-2023)
  • Table 15. South America IHC Daignostics, by Type USD Million (2018-2023)
  • Table 16. South America IHC Daignostics, by Application USD Million (2018-2023)
  • Table 17. South America IHC Daignostics, by End User USD Million (2018-2023)
  • Table 18. Brazil IHC Daignostics, by Type USD Million (2018-2023)
  • Table 19. Brazil IHC Daignostics, by Application USD Million (2018-2023)
  • Table 20. Brazil IHC Daignostics, by End User USD Million (2018-2023)
  • Table 21. Argentina IHC Daignostics, by Type USD Million (2018-2023)
  • Table 22. Argentina IHC Daignostics, by Application USD Million (2018-2023)
  • Table 23. Argentina IHC Daignostics, by End User USD Million (2018-2023)
  • Table 24. Rest of South America IHC Daignostics, by Type USD Million (2018-2023)
  • Table 25. Rest of South America IHC Daignostics, by Application USD Million (2018-2023)
  • Table 26. Rest of South America IHC Daignostics, by End User USD Million (2018-2023)
  • Table 27. Asia Pacific IHC Daignostics, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific IHC Daignostics, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific IHC Daignostics, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific IHC Daignostics, by End User USD Million (2018-2023)
  • Table 31. China IHC Daignostics, by Type USD Million (2018-2023)
  • Table 32. China IHC Daignostics, by Application USD Million (2018-2023)
  • Table 33. China IHC Daignostics, by End User USD Million (2018-2023)
  • Table 34. Japan IHC Daignostics, by Type USD Million (2018-2023)
  • Table 35. Japan IHC Daignostics, by Application USD Million (2018-2023)
  • Table 36. Japan IHC Daignostics, by End User USD Million (2018-2023)
  • Table 37. India IHC Daignostics, by Type USD Million (2018-2023)
  • Table 38. India IHC Daignostics, by Application USD Million (2018-2023)
  • Table 39. India IHC Daignostics, by End User USD Million (2018-2023)
  • Table 40. South Korea IHC Daignostics, by Type USD Million (2018-2023)
  • Table 41. South Korea IHC Daignostics, by Application USD Million (2018-2023)
  • Table 42. South Korea IHC Daignostics, by End User USD Million (2018-2023)
  • Table 43. Taiwan IHC Daignostics, by Type USD Million (2018-2023)
  • Table 44. Taiwan IHC Daignostics, by Application USD Million (2018-2023)
  • Table 45. Taiwan IHC Daignostics, by End User USD Million (2018-2023)
  • Table 46. Australia IHC Daignostics, by Type USD Million (2018-2023)
  • Table 47. Australia IHC Daignostics, by Application USD Million (2018-2023)
  • Table 48. Australia IHC Daignostics, by End User USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific IHC Daignostics, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific IHC Daignostics, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific IHC Daignostics, by End User USD Million (2018-2023)
  • Table 52. Europe IHC Daignostics, by Country USD Million (2018-2023)
  • Table 53. Europe IHC Daignostics, by Type USD Million (2018-2023)
  • Table 54. Europe IHC Daignostics, by Application USD Million (2018-2023)
  • Table 55. Europe IHC Daignostics, by End User USD Million (2018-2023)
  • Table 56. Germany IHC Daignostics, by Type USD Million (2018-2023)
  • Table 57. Germany IHC Daignostics, by Application USD Million (2018-2023)
  • Table 58. Germany IHC Daignostics, by End User USD Million (2018-2023)
  • Table 59. France IHC Daignostics, by Type USD Million (2018-2023)
  • Table 60. France IHC Daignostics, by Application USD Million (2018-2023)
  • Table 61. France IHC Daignostics, by End User USD Million (2018-2023)
  • Table 62. Italy IHC Daignostics, by Type USD Million (2018-2023)
  • Table 63. Italy IHC Daignostics, by Application USD Million (2018-2023)
  • Table 64. Italy IHC Daignostics, by End User USD Million (2018-2023)
  • Table 65. United Kingdom IHC Daignostics, by Type USD Million (2018-2023)
  • Table 66. United Kingdom IHC Daignostics, by Application USD Million (2018-2023)
  • Table 67. United Kingdom IHC Daignostics, by End User USD Million (2018-2023)
  • Table 68. Netherlands IHC Daignostics, by Type USD Million (2018-2023)
  • Table 69. Netherlands IHC Daignostics, by Application USD Million (2018-2023)
  • Table 70. Netherlands IHC Daignostics, by End User USD Million (2018-2023)
  • Table 71. Rest of Europe IHC Daignostics, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe IHC Daignostics, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe IHC Daignostics, by End User USD Million (2018-2023)
  • Table 74. MEA IHC Daignostics, by Country USD Million (2018-2023)
  • Table 75. MEA IHC Daignostics, by Type USD Million (2018-2023)
  • Table 76. MEA IHC Daignostics, by Application USD Million (2018-2023)
  • Table 77. MEA IHC Daignostics, by End User USD Million (2018-2023)
  • Table 78. Middle East IHC Daignostics, by Type USD Million (2018-2023)
  • Table 79. Middle East IHC Daignostics, by Application USD Million (2018-2023)
  • Table 80. Middle East IHC Daignostics, by End User USD Million (2018-2023)
  • Table 81. Africa IHC Daignostics, by Type USD Million (2018-2023)
  • Table 82. Africa IHC Daignostics, by Application USD Million (2018-2023)
  • Table 83. Africa IHC Daignostics, by End User USD Million (2018-2023)
  • Table 84. North America IHC Daignostics, by Country USD Million (2018-2023)
  • Table 85. North America IHC Daignostics, by Type USD Million (2018-2023)
  • Table 86. North America IHC Daignostics, by Application USD Million (2018-2023)
  • Table 87. North America IHC Daignostics, by End User USD Million (2018-2023)
  • Table 88. United States IHC Daignostics, by Type USD Million (2018-2023)
  • Table 89. United States IHC Daignostics, by Application USD Million (2018-2023)
  • Table 90. United States IHC Daignostics, by End User USD Million (2018-2023)
  • Table 91. Canada IHC Daignostics, by Type USD Million (2018-2023)
  • Table 92. Canada IHC Daignostics, by Application USD Million (2018-2023)
  • Table 93. Canada IHC Daignostics, by End User USD Million (2018-2023)
  • Table 94. Mexico IHC Daignostics, by Type USD Million (2018-2023)
  • Table 95. Mexico IHC Daignostics, by Application USD Million (2018-2023)
  • Table 96. Mexico IHC Daignostics, by End User USD Million (2018-2023)
  • Table 97. IHC Daignostics: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. IHC Daignostics: by Type(USD Million)
  • Table 114. IHC Daignostics Antibodies [Primary antibodies, Secondary antibodies] , by Region USD Million (2025-2030)
  • Table 115. IHC Daignostics Reagents [Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents] , by Region USD Million (2025-2030)
  • Table 116. IHC Daignostics Equipment [Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment ] , by Region USD Million (2025-2030)
  • Table 117. IHC Daignostics Kits [IHC Kits for Human tissue, IHC Kits for Animal tissue] , by Region USD Million (2025-2030)
  • Table 118. IHC Daignostics: by Application(USD Million)
  • Table 119. IHC Daignostics Diagnostic applications [Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other ] , by Region USD Million (2025-2030)
  • Table 120. IHC Daignostics Research applications [Drug development and Testing, Other] , by Region USD Million (2025-2030)
  • Table 121. IHC Daignostics Forensic applications , by Region USD Million (2025-2030)
  • Table 122. IHC Daignostics: by End User(USD Million)
  • Table 123. IHC Daignostics Hospitals & Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 124. IHC Daignostics Academic & Research Institutes , by Region USD Million (2025-2030)
  • Table 125. IHC Daignostics Other , by Region USD Million (2025-2030)
  • Table 126. South America IHC Daignostics, by Country USD Million (2025-2030)
  • Table 127. South America IHC Daignostics, by Type USD Million (2025-2030)
  • Table 128. South America IHC Daignostics, by Application USD Million (2025-2030)
  • Table 129. South America IHC Daignostics, by End User USD Million (2025-2030)
  • Table 130. Brazil IHC Daignostics, by Type USD Million (2025-2030)
  • Table 131. Brazil IHC Daignostics, by Application USD Million (2025-2030)
  • Table 132. Brazil IHC Daignostics, by End User USD Million (2025-2030)
  • Table 133. Argentina IHC Daignostics, by Type USD Million (2025-2030)
  • Table 134. Argentina IHC Daignostics, by Application USD Million (2025-2030)
  • Table 135. Argentina IHC Daignostics, by End User USD Million (2025-2030)
  • Table 136. Rest of South America IHC Daignostics, by Type USD Million (2025-2030)
  • Table 137. Rest of South America IHC Daignostics, by Application USD Million (2025-2030)
  • Table 138. Rest of South America IHC Daignostics, by End User USD Million (2025-2030)
  • Table 139. Asia Pacific IHC Daignostics, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific IHC Daignostics, by Type USD Million (2025-2030)
  • Table 141. Asia Pacific IHC Daignostics, by Application USD Million (2025-2030)
  • Table 142. Asia Pacific IHC Daignostics, by End User USD Million (2025-2030)
  • Table 143. China IHC Daignostics, by Type USD Million (2025-2030)
  • Table 144. China IHC Daignostics, by Application USD Million (2025-2030)
  • Table 145. China IHC Daignostics, by End User USD Million (2025-2030)
  • Table 146. Japan IHC Daignostics, by Type USD Million (2025-2030)
  • Table 147. Japan IHC Daignostics, by Application USD Million (2025-2030)
  • Table 148. Japan IHC Daignostics, by End User USD Million (2025-2030)
  • Table 149. India IHC Daignostics, by Type USD Million (2025-2030)
  • Table 150. India IHC Daignostics, by Application USD Million (2025-2030)
  • Table 151. India IHC Daignostics, by End User USD Million (2025-2030)
  • Table 152. South Korea IHC Daignostics, by Type USD Million (2025-2030)
  • Table 153. South Korea IHC Daignostics, by Application USD Million (2025-2030)
  • Table 154. South Korea IHC Daignostics, by End User USD Million (2025-2030)
  • Table 155. Taiwan IHC Daignostics, by Type USD Million (2025-2030)
  • Table 156. Taiwan IHC Daignostics, by Application USD Million (2025-2030)
  • Table 157. Taiwan IHC Daignostics, by End User USD Million (2025-2030)
  • Table 158. Australia IHC Daignostics, by Type USD Million (2025-2030)
  • Table 159. Australia IHC Daignostics, by Application USD Million (2025-2030)
  • Table 160. Australia IHC Daignostics, by End User USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific IHC Daignostics, by Type USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific IHC Daignostics, by Application USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific IHC Daignostics, by End User USD Million (2025-2030)
  • Table 164. Europe IHC Daignostics, by Country USD Million (2025-2030)
  • Table 165. Europe IHC Daignostics, by Type USD Million (2025-2030)
  • Table 166. Europe IHC Daignostics, by Application USD Million (2025-2030)
  • Table 167. Europe IHC Daignostics, by End User USD Million (2025-2030)
  • Table 168. Germany IHC Daignostics, by Type USD Million (2025-2030)
  • Table 169. Germany IHC Daignostics, by Application USD Million (2025-2030)
  • Table 170. Germany IHC Daignostics, by End User USD Million (2025-2030)
  • Table 171. France IHC Daignostics, by Type USD Million (2025-2030)
  • Table 172. France IHC Daignostics, by Application USD Million (2025-2030)
  • Table 173. France IHC Daignostics, by End User USD Million (2025-2030)
  • Table 174. Italy IHC Daignostics, by Type USD Million (2025-2030)
  • Table 175. Italy IHC Daignostics, by Application USD Million (2025-2030)
  • Table 176. Italy IHC Daignostics, by End User USD Million (2025-2030)
  • Table 177. United Kingdom IHC Daignostics, by Type USD Million (2025-2030)
  • Table 178. United Kingdom IHC Daignostics, by Application USD Million (2025-2030)
  • Table 179. United Kingdom IHC Daignostics, by End User USD Million (2025-2030)
  • Table 180. Netherlands IHC Daignostics, by Type USD Million (2025-2030)
  • Table 181. Netherlands IHC Daignostics, by Application USD Million (2025-2030)
  • Table 182. Netherlands IHC Daignostics, by End User USD Million (2025-2030)
  • Table 183. Rest of Europe IHC Daignostics, by Type USD Million (2025-2030)
  • Table 184. Rest of Europe IHC Daignostics, by Application USD Million (2025-2030)
  • Table 185. Rest of Europe IHC Daignostics, by End User USD Million (2025-2030)
  • Table 186. MEA IHC Daignostics, by Country USD Million (2025-2030)
  • Table 187. MEA IHC Daignostics, by Type USD Million (2025-2030)
  • Table 188. MEA IHC Daignostics, by Application USD Million (2025-2030)
  • Table 189. MEA IHC Daignostics, by End User USD Million (2025-2030)
  • Table 190. Middle East IHC Daignostics, by Type USD Million (2025-2030)
  • Table 191. Middle East IHC Daignostics, by Application USD Million (2025-2030)
  • Table 192. Middle East IHC Daignostics, by End User USD Million (2025-2030)
  • Table 193. Africa IHC Daignostics, by Type USD Million (2025-2030)
  • Table 194. Africa IHC Daignostics, by Application USD Million (2025-2030)
  • Table 195. Africa IHC Daignostics, by End User USD Million (2025-2030)
  • Table 196. North America IHC Daignostics, by Country USD Million (2025-2030)
  • Table 197. North America IHC Daignostics, by Type USD Million (2025-2030)
  • Table 198. North America IHC Daignostics, by Application USD Million (2025-2030)
  • Table 199. North America IHC Daignostics, by End User USD Million (2025-2030)
  • Table 200. United States IHC Daignostics, by Type USD Million (2025-2030)
  • Table 201. United States IHC Daignostics, by Application USD Million (2025-2030)
  • Table 202. United States IHC Daignostics, by End User USD Million (2025-2030)
  • Table 203. Canada IHC Daignostics, by Type USD Million (2025-2030)
  • Table 204. Canada IHC Daignostics, by Application USD Million (2025-2030)
  • Table 205. Canada IHC Daignostics, by End User USD Million (2025-2030)
  • Table 206. Mexico IHC Daignostics, by Type USD Million (2025-2030)
  • Table 207. Mexico IHC Daignostics, by Application USD Million (2025-2030)
  • Table 208. Mexico IHC Daignostics, by End User USD Million (2025-2030)
  • Table 209. IHC Daignostics: by Type(USD/Units)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global IHC Daignostics: by Type USD Million (2018-2023)
  • Figure 5. Global IHC Daignostics: by Application USD Million (2018-2023)
  • Figure 6. Global IHC Daignostics: by End User USD Million (2018-2023)
  • Figure 7. South America IHC Daignostics Share (%), by Country
  • Figure 8. Asia Pacific IHC Daignostics Share (%), by Country
  • Figure 9. Europe IHC Daignostics Share (%), by Country
  • Figure 10. MEA IHC Daignostics Share (%), by Country
  • Figure 11. North America IHC Daignostics Share (%), by Country
  • Figure 12. Global IHC Daignostics: by Type USD/Units (2018-2023)
  • Figure 13. Global IHC Daignostics share by Players 2023 (%)
  • Figure 14. Global IHC Daignostics share by Players (Top 3) 2023(%)
  • Figure 15. Global IHC Daignostics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 19. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Bio-Techne Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Techne Corporation (United States) Revenue: by Geography 2023
  • Figure 23. F. Hoffman-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffman-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 27. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Agilent Technologies, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Abcam plc (UK) Revenue, Net Income and Gross profit
  • Figure 30. Abcam plc (UK) Revenue: by Geography 2023
  • Figure 31. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Becton, Dickinson, and Company (United States) Revenue: by Geography 2023
  • Figure 33. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. PerkinElmer, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Takara Bio, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Takara Bio, Inc. (Japan) Revenue: by Geography 2023
  • Figure 37. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Diagnostic Biosystems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Diagnostic Biosystems, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. BioVision Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. BioVision Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Rockland Immunochemicals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Rockland Immunochemicals, Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Genemed Biotechnologies, Inc. (United States). Revenue, Net Income and Gross profit
  • Figure 46. Genemed Biotechnologies, Inc. (United States). Revenue: by Geography 2023
  • Figure 47. Global IHC Daignostics: by Type USD Million (2025-2030)
  • Figure 48. Global IHC Daignostics: by Application USD Million (2025-2030)
  • Figure 49. Global IHC Daignostics: by End User USD Million (2025-2030)
  • Figure 50. South America IHC Daignostics Share (%), by Country
  • Figure 51. Asia Pacific IHC Daignostics Share (%), by Country
  • Figure 52. Europe IHC Daignostics Share (%), by Country
  • Figure 53. MEA IHC Daignostics Share (%), by Country
  • Figure 54. North America IHC Daignostics Share (%), by Country
  • Figure 55. Global IHC Daignostics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Bio-Rad Laboratories, Inc. (United States)
  • Bio-Techne Corporation (United States)
  • F. Hoffman-La Roche AG (Switzerland)
  • Danaher Corporation (United States)
  • Agilent Technologies, Inc. (United States)
  • Abcam plc (UK)
  • Becton, Dickinson, and Company (United States)
  • PerkinElmer, Inc. (United States)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (United States)
  • Diagnostic Biosystems, Inc. (United States)
  • BioVision Inc. (United States)
  • Rockland Immunochemicals, Inc. (United States)
  • Genemed Biotechnologies, Inc. (United States).
Additional players considered in the study are as follows:
PHC Holdings Corporation (Japan) , Cell Signaling Technology, Inc. (United States) , Bio SB, Inc. (United States) , Miltenyi Biotec (Germany) , CANDOR Bioscience GmbH (Germany) , Sakura Finetek Japan Co., Ltd. (Japan) , Eagle Biosciences, Inc. (United States) , Biocare Medical, LLC (United States) , Elabscience, Inc. (China) , Biogenex Laboratories (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 201 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global IHC Daignostics Market Quantitative research analysis
Global IHC Daignostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (United States), Bio-Techne Corporation (United States), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (United States), Agilent Technologies, Inc. (United States), Abcam plc (UK), Becton, Dickinson, and Company (United States), PerkinElmer, Inc. (United States), Takara Bio, Inc. (Japan), Thermo Fisher Scientific, Inc. (United States), Diagnostic Biosystems, Inc. (United States), BioVision Inc. (United States), Rockland Immunochemicals, Inc. (United States) and Genemed Biotechnologies, Inc. (United States). etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"In the field of IHC, technological improvements have been made. " is seen as one of major influencing trends for IHC Daignostics Market during projected period 2023-2030.
The IHC Daignostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global IHC Daignostics Market Report?

Have a Query? Click Here

Other Related Reports

Clostridium Vaccine Animal Health Comprehensive Study by Distribution Channel (Veterinary Clinic, Veterinary Hospital, Veterinary Research institute, Retail Pharmacy), Animal Species (Bovine, Ovine, ...
$ 3500
Urology Comprehensive Study by Therapies (Medications, Surgery {Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), Transurethral Electrovaporization, Holmi...
$ 3800
Antibody Discovery Comprehensive Study by Type (Monoclonal Antibodies, Polyclonal Antibodies, Other Antibodies), Application (Healthcare Industry), Nature (Humanized, Human, Chimeric, Murine), Method...
$ 3800
Shoulder Impingement Syndrome Comprehensive Study by Type (Structural, Functional), Shoulder Impingement Syndrome (Anterior Acromial Impingement, Posterosuperior Glenoid Rim Impingement, Subcoracoid ...
$ 4000
In-vivo Contract Research Organization Comprehensive Study by Services (Clinical Trials, Research Support), Therapeutic Areas (Autoimmune, Pain Management, Oncology, Nephrology, Diabetes, Cardiovascu...
$ 3800
Heart Transplant Comprehensive Study by Demographics (Gender, -Male, -Female, -Unisex, Age, -0-10 Years, -11-29 Years, -30-49 Years, -50-69 Years, Others), End Users (Hospitals, Cardiac Institute, Ot...
$ 3800